Foto del docente

Roberto Bernardoni

Assistant professor

Department of Pharmacy and Biotechnology

Academic discipline: BIO/18 Genetics


Keywords: Animal model for BcrAbl-positive Leukemia MULTIDRUG RESISTANCE CHROMATIN IMMUNOPRECIPITATION Antileukemic drugs N-MYC ONCOGENE

I. N-Myc transcriptional regulation of gene coding for neurotrophin receptors (p75NTR, TrkA) and ABC (ATP Binding Cassete Transporters) in neuroblastoma.

II. Set up and characterization of an animal model trhat recapitulates the mechanisms that cause a block of cell differentiation dependent on an excess of the MYC oncoprotein in a MAX-indepndent manner.
III. Set-up and characterization of an drosophila model of BcrAbl+ Leukemias for genetic and pharmacological screens (external advice; in collaborazione con Prof. G. Saglio, Dr. D. Cillone e Dr. F. Messa (divisione di Ematologia e Medicina Interna, Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Orbassano (Torino).
IV. In vivo analysis of the mechanism of action of a new anti-leukemic drug class (SMO protein inhibitor) studied to contrast the relapse in Chronic Myelogenous Leukemia patients.

II. The Myc family is formed by three oncoproteins c-Myc, N-Myc and L-Myc each able to heterodimerize with the Max-family factors and to work as transcription factors. The identification of the Myc's target genes is the key step to understand its role in cancer biology and particularly in cancer where myc is amplified or overexpressed. We have identified as putative Myc target genes the ones coding for the neurotrophin receptors (p75NTR and TrkA) and for some ABC (ATP Binding Cassette) transporters. We are currently: i) defining how N-Myc regulates transcritpion of the above cited genes in neuroblastoma cells; ii) Verifying that Myc controls multidrug resistance especially in cancer stem-cells